Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity

Trial Profile

Physiologic Effects of Long-Term GHRH1-44 in Abdominal Obesity

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Nov 2012 Status changed from active, no longer recruiting to completed.
    • 26 Sep 2012 Results published in the Journal of Clinical Endocrinology and Metabolism.
    • 27 Jun 2012 Primary endpoint 'Visceral-adipose tissue' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top